Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Outlook 2026–2035 Driven by Key Growth Factors and Industry Projections
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Anticipated For The Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Over The Period 2026–2030?
The antineutrophil cytoplasmic antibody (anca) associated vasculitis market size has experienced robust growth in recent years. It is projected to increase from $0.63 billion in 2025 to $0.68 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.7%. The expansion observed in the historic period can be ascribed to improvements in autoimmune disease diagnostics, increased use of corticosteroids and immunosuppressants, expansion of nephrology and rheumatology care services, growing clinical awareness of rare vasculitis disorders, and the availability of standardized treatment protocols.
The antineutrophil cytoplasmic antibody (anca) associated vasculitis market size is anticipated to show considerable growth over the next few years, projected to reach $0.95 billion by 2030, with a compound annual growth rate (CAGR) of 8.6%. This expected growth during the forecast period can be attributed to the increasing development of targeted biologics, rising investments in rare disease research, the expansion of personalized treatment approaches, a growing focus on relapse prevention strategies, and increasing patient access to specialized care centers. Prominent trends within this period include the rising adoption of biologic therapies, an increased focus on early and accurate diagnosis, the growing use of targeted immunosuppressive treatments, the expansion of multidisciplinary disease management approaches, and an enhanced emphasis on long-term disease monitoring.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23309&type=smp
Which Economic Or Industry Drivers Are Impacting The Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market?
The increasing occurrence of autoimmune diseases is anticipated to fuel the expansion of the ANCA-associated vasculitis market moving forward. These conditions arise when the immune system mistakenly attacks the body’s healthy cells and tissues, perceiving them as foreign threats like bacteria or viruses. The growing incidence of autoimmune diseases stems from environmental triggers and lifestyle factors, with greater exposure to infections and pollutants contributing significantly by disrupting immune tolerance and initiating abnormal immune responses. Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis plays a crucial role in advancing autoimmune disease research and treatment by fostering the development of targeted immunosuppressive therapies, enhancing early diagnostic capabilities, and improving overall disease management strategies, ultimately leading to better patient outcomes and a deeper understanding of immune system regulation. For instance, in September 2023, according to the Impact of IBD Report 2023 published by the Inflammatory Bowel Disease (IBD) Clinical and Research Centre, a Canada-based organization focused on improving the lives of patients with Crohn’s disease and ulcerative colitis, in 2023, the prevalence of inflammatory bowel disease (IBD), an autoimmune disease, in Canada was 825 per 100,000 people, affecting over 320,000 individuals. With an expected annual increase of 2.44% in prevalence, it is projected that by 2035, approximately 470,000 Canadians, representing 1.1% of the population, will be living with IBD. Consequently, the rising incidence of autoimmune diseases is set to drive the ANCA-associated vasculitis market.
How Is The Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Divided Into Its Major Segments?
The antineutrophil cytoplasmic antibody (anca) associated vasculitis market covered in this report is segmented –
1) By Type: Granulomatosis With Polyangiitis (GPA Or Wegener’s), Microscopic Polyangiitis (MPA), Eosinophilic Granulomatosis With Polyangiitis (EGPA Or Churg-Strauss), Other Types
2) By Treatment: Immunosuppressants, Corticosteroids, Biologics, Other Treatments
3) By Diagnosis: Blood Tests, Biopsy, Imaging, Other Diagnosis
Subsegments:
1) By Granulomatosis With Polyangiitis (GPA or Wegener’s): Limited Granulomatosis With Polyangiitis, Severe Granulomatosis With Polyangiitis, Refractory Granulomatosis With Polyangiitis
2) By Microscopic Polyangiitis (MPA): Renal Microscopic Polyangiitis, Pulmonary Microscopic Polyangiitis, Neurological Microscopic Polyangiitis
3) By Eosinophilic Granulomatosis With Polyangiitis (EGPA or Churg-Strauss): Cardiac Eosinophilic Granulomatosis With Polyangiitis, Pulmonary Eosinophilic Granulomatosis With Polyangiitis, Neurological Eosinophilic Granulomatosis With Polyangiitis
4) By Other Types: Drug-Induced ANCA-Associated Vasculitis, Infection-Related ANCA-Associated Vasculitis, Overlap Syndrome ANCA-Associated Vasculitis
Which Trends Are Impacting The Growth Of The Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market?
Leading companies in the ANCA-associated vasculitis market are concentrating on developing innovative solutions, such as targeted therapies, to offer new treatment options for patients with this rare and severe condition. Targeted therapy for ANCA-associated vasculitis involves utilizing specialized biologic agents to selectively inhibit immune system components responsible for inflammation and vascular damage, thereby reducing disease progression and minimizing treatment-related toxicity. For instance, in February 2023, Vifor Fresenius Medical Care Renal Pharma (VFMCRP), a Switzerland-based pharmaceutical company, announced the approval of Tavneos (avacopan) by the Therapeutic Goods Administration (TGA), an Australia-based government regulatory agency, for the treatment of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), in combination with rituximab or cyclophosphamide-based regimen. This approval signifies a major advancement as Tavneos is the first targeted therapy designed specifically for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), the two primary forms of ANCA-associated vasculitis. By selectively inhibiting the complement C5a receptor (C5aR1), the therapy helps manage inflammation and disease progression while reducing the reliance on high-dose glucocorticoids (steroids), which are known for severe long-term side effects.
Who Are The Prominent Organizations Shaping The Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market?
Major companies operating in the antineutrophil cytoplasmic antibody (anca) associated vasculitis market are ChemoCentryx Inc, Amgen Inc, AstraZeneca Plc, GlaxoSmithKline plc, Novartis AG, Bristol-Myers Squibb Company, Travere Therapeutics Inc, F. Hoffmann-La Roche AG, Pfizer Inc, Sanofi SA, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, AbbVie Inc, UCB S.A., Bayer AG, Janssen Pharmaceuticals NV, Sobi AB, Alentis Therapeutics AG, InflaRx NV, NS Pharma Inc, Staidson Biopharmaceuticals Co Ltd, Genentech Inc, Regeneron Pharmaceuticals Inc, Mylan NV, Teva Pharmaceutical Industries Ltd, Biogen Inc, CSL Limited, Moderna Inc, Vertex Pharmaceuticals Inc.
Read the full antineutrophil cytoplasmic antibody (anca) associated vasculitis market report here:
What Are The Top-Performing Regions Within The Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market?
North America was the largest region in the antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antineutrophil cytoplasmic antibody (anca) associated vasculitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=23309&type=smp
Browse Through More Reports Similar to the Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market 2026, By The Business Research Company
Veterinary Antimicrobial Susceptibility Testing Global Market Report
Gastrointestinal Pathogen Testing Global Market Report
Infectious Disease Diagnostics Testing Global Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
